# CellMax Life

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cellmax-life

- Industry: Biotechnology
- Headquarters: Sunnyvale, US
- Website: http://www.cellmaxlife.com
- Total disclosed funding: $14M
- Latest round: Series A (Jul 26, 2016)
- Investors on record: 1

## About

CellMax Life offers innovative screening solutions specifically designed for colorectal cancer, centered on their flagship FirstSight™ blood test that detects precancerous adenomas, enhancing early diagnosis and prevention for patients.Founded in 2013 and headquartered in Sunnyvale, US, CellMax Life focuses on advanced solutions for colorectal cancer screening. The company has successfully raised USD 9.00 mn through a SERIES A funding round led by Artiman Ventures in July 2016. Ben Hsieh, Jia L., and Ying C are among the founders, with Atul Sharan serving as CEO.CellMax Life specializes in innovative solutions for colorectal cancer screening and prevention, with a primary focus on their flagship product, FirstSight™, which is recognized as the first blood test designed specifically for adenoma detection. This proprietary blood test functions by identifying precancerous polyps, known as adenomas, which are critical to monitor as their removal has been shown to reduce colorectal cancer mortality by 53%. The company targets a substantial client base, including healthcare providers and institutions that follow national guidelines recommending routine screenings for over 125 million Americans. CellMax Life's products are primarily marketed in the United States, complemented by operations in Taiwan, thereby addressing a global audience concerned with colorectal cancer prevention and early detection. The end users of their services are patients undergoing routine screenings, along with healthcare professionals who utilize the test results to inform patient care decisions.CellMax Life generates revenue through the direct provision of its FirstSight™ blood test to healthcare providers and facilities that incorporate it into their routine screening protocols. The business model involves partnerships with medical institutions, enabling them to offer this innovative screening solution to their patients. Revenue transactions are structured around service agreements with these providers, where the test is administered to patients, and results are analyzed and reported back to the healthcare professionals. This operational setup allows for streamlined processes in testing and result dissemination, ensuring that patients receive timely information regarding their health status. Specific pricing plans for the FirstSight™ test and other services are structured based on agreements with healthcare entities, reflecting the value of early detection in preventing the disease and associated healthcare costs.CellMax Life aims to expand its product offerings and market presence. The company is focused on developing additional innovative screening products designed to enhance early detection capabilities. With the funds raised in the SERIES A round in July 2016, totaling USD 9.00 mn, CellMax Life plans to enhance its marketing efforts and expand into new geographic markets, specifically targeting additional regions within the US and potentially expanding its operations further in Taiwan by the end of 2017.

## Funding rounds

- Series A, Jul 26, 2016, $9M — Artiman Ventures
- Series A, Jun 1, 2013, $5M — Artiman Ventures

## Investors

- Artiman Ventures (https://capitalatlas.ai/funds/artiman-ventures) — Series A